论文部分内容阅读
免疫治疗是恶性肿瘤综合治疗的重要部分。以往被动免疫治疗虽有肯定的抗肿瘤作用,但疗效短、全身反应大,主要受到抗血清特异性和数量的限制。因为用常规方法制备对人肿瘤细胞具有特异性的异种抗血清,需要用正常组织进行广泛的吸收,即便这样,仍然与正常组织常有交叉反应。大量制备这种抗血清是很困难的,且抗体滴度低,其中混有大量异体蛋白,临床运用可发生致命的过敏反应。自从淋巴细胞杂交瘤技术创立以来,持续地获得高浓度的对任何特定抗原决定基的均一抗体,即单克隆抗体(MoAb)已有可能。随着这一技术的迅速发展,用MoAb治疗恶性
Immunotherapy is an important part of the comprehensive treatment of malignant tumors. Past passive immunotherapy although positive anti-tumor effect, but the short response, systemic response, mainly due to antisera specific and quantitative restrictions. Because heterologous antisera that is specific for human tumor cells are prepared by conventional methods, they require extensive absorption from normal tissues, and even then, they often cross-react with normal tissues. The preparation of such antisera in large quantities is very difficult, and the antibody titer is low, in which a large amount of foreign protein is mixed, and a fatal anaphylactic reaction can occur in clinical use. Since the establishment of lymphocyte hybridoma technology, it has been possible to obtain consistently high concentrations of a monoclonal antibody (MoAb) that is a uniform antibody to any particular epitope. With the rapid development of this technology, the treatment of malignancy with MoAb